Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
18 Maggio 2023 - 12:00PM
Business Wire
ADI-270 includes Adicet’s proprietary armoring
technology and enhancements designed for improved persistence and
durability within a solid tumor microenvironment (TME)
ADI-270 demonstrated potent anti-tumor activity
in CD70+ cancers and improved resilience to clearance from host
immune targeting
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for cancer, today announced preclinical data highlighting
ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR
(chimeric antigen receptor) T cell therapy candidate targeting
CD70+ cancers, at the 26th Annual Meeting of the American Society
of Gene & Cell Therapy (ASGCT) taking place from May 16-20,
2023, in Los Angeles, CA.
“We believe that ADI-270, combined with a third generation CAR
and armoring technologies designed to improve persistence and
resilience within the TME, may be able to overcome multiple
barriers for realizing efficacy for cell therapies in solid tumors.
Together with both innate and adaptive immune targeting and tumor
infiltration, we believe ADI-270 can potentially improve clinical
outcomes for patients,” said Dr. Blake Aftab, Ph.D., Chief
Scientific Officer of Adicet. “These findings provide critical
groundwork to support the continued clinical development of ADI-270
as a potentially meaningful therapeutic option.”
In this study, gamma delta T cells modified to express CD70 CAR
were successfully generated and expanded without evident hindrances
from CD70-mediated fratricide in the process. Data being presented
included the following findings:
- ADI-270 demonstrated preclinical proof-of-concept as an armored
allogeneic gamma delta CAR T cell therapy candidate utilizing the
CD27 natural receptor in a third generation CAR format for
targeting CD70-positive cancers.
- ADI-270 gamma delta 1 CAR T cells expressed a predominant
naïve-like memory phenotype with potent in vitro cytotoxicity and
production of proinflammatory cytokines against CD70+ tumor cell
lines via multiple mechanisms.
- ADI-270 showed significant inhibition of tumor growth in CD70+
tumor cell lines, which was maintained in the presence of TGF beta
inhibitory factor, and exhibited improved resistance to killing by
host T cell rejection.
- ADI-270 also demonstrated marked biodistribution and
infiltration into solid tumor models of renal cell carcinoma.
Details for the poster presentations are as follows:
Title: ADI-270: An Armored Allogeneic “Off-the-Shelf” CAR
gamma delta T Cell therapy Targeting CD70+ Cancers
Abstract Number: 1023 Poster Session: Thursday
Poster Session Date & Time: May 18, 2023 at noon
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma
delta T cells, engineered with chimeric antigen receptors (CARs)
and chimeric antigen adaptors (CAds), to enhance selective tumor
targeting and facilitate innate and adaptive anti-tumor immune
response for durable activity in patients. For more information,
please visit our website at https://www.adicetbio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to the business and operations of
Adicet. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include, but
are not limited to, express or implied statements regarding:
preclinical and clinical development of Adicet’s product
candidates, including future plans or expectations for ADI-270.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including without limitation, Adicet’s ability to execute on its
strategy including obtaining the requisite regulatory approvals on
the expected timeline, if at all; that positive results, including
interim results, from a preclinical or clinical study may not
necessarily be predictive of the results of future or ongoing
studies; clinical studies may fail to demonstrate adequate safety
and efficacy of Adicet’s product candidates, which would prevent,
delay, or limit the scope of regulatory approval and
commercialization; regulatory approval processes of the FDA and
comparable foreign regulatory authorities are lengthy,
time-consuming, and inherently unpredictable; Adicet’s ability to
meet production and product release expectations; the effect of
COVID-19 on Adicet’s business and financial results, including with
respect to disruptions to our preclinical and clinical trials,
business operations, employee hiring and retention, and ability to
raise additional capital. For a discussion of these and other risks
and uncertainties, and other important factors, any of which could
cause Adicet’s actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in Adicet’s most recent annual report on Form 10-K and our periodic
reports on Form 10-Q and Form 8-K filed with the SEC, as well as
discussions of potential risks, uncertainties, and other important
factors in Adicet’s other filings with the SEC. All information in
this press release is as of the date of the release, and Adicet
undertakes no duty to update this information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230518005191/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Adicet Bio (NASDAQ:ACET)
Storico
Da Set 2023 a Set 2024